Atypical Parkinsonian Disorders Comparison

Atypical Parkinsonian Disorders Comparison

Atypical Parkinsonian Disorders: MSA, PSP, CBD Comparison

The atypical parkinsonian disorders — Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) — share features with Parkinson's disease but exhibit distinct pathological mechanisms, faster disease trajectories, and therapeutic responses.[@kalia2015] This page provides a comprehensive comparison of these three disorders.

Overview

All three disorders exhibit:

• Parkinsonian features (bradykinesia, rigidity, tremor)
• Poor levodopa response (unlike classic PD)
• Additional neurological involvement (cortical, cerebellar, autonomic)
• Faster progression than typical PD

However, the underlying pathology and mechanisms differ substantially.

```mermaid
flowchart TD
Root["Atypical Parkinsonian Disorders"] --> Syn["Alpha-synucleinopathy"]
Root --> Tau["4R Tauopathy"]

Syn --> MSA["MSA<br/>oligodendroglial GCIs"]
Syn --> DLB["DLB<br/>neuronal Lewy bodies"]
Tau --> PSP["PSP<br/>tufted astrocytes"]
Tau --> CBD["CBD<br/>astrocytic plaques"]

MSA --> Auto["Early autonomic failure<br/>cerebellar signs"]
PSP --> Gaze["Vertical gaze palsy<br/>early falls"]
CBD --> Asym["Asymmetric apraxia<br/>alien limb"]
DLB --> Cog["Fluctuating cognition<br/>visual hallucinations"]

...

Atypical Parkinsonian Disorders Comparison

Atypical Parkinsonian Disorders: MSA, PSP, CBD Comparison

The atypical parkinsonian disorders — Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) — share features with Parkinson's disease but exhibit distinct pathological mechanisms, faster disease trajectories, and therapeutic responses.[@kalia2015] This page provides a comprehensive comparison of these three disorders.

Overview

All three disorders exhibit:

• Parkinsonian features (bradykinesia, rigidity, tremor)
• Poor levodopa response (unlike classic PD)
• Additional neurological involvement (cortical, cerebellar, autonomic)
• Faster progression than typical PD

However, the underlying pathology and mechanisms differ substantially.

Pathological Classification

| Disorder | Primary Protein | Primary Cell Target | Inclusions |
|----------|----------------|---------------------|-------------|
| MSA | Alpha-synuclein | Oligodendrocytes | GCI |
| PSP | 4R Tau | Neurons, Astrocytes | NFTs, Tufted astrocytes |
| CBD | 4R Tau | Neurons, Astrocytes | NFTs, Astrocytic plaques |

Alpha-Synucleinopathies: MSA

[MSA](/diseases/multiple-system-atrophy) is characterized by:

• Glial cytoplasmic inclusions (GCIs) — pathognomonic alpha-synuclein aggregates in oligodendrocytes
• Striatonigral degeneration — loss of dopaminergic neurons in putamen and substantia nigra
• Pontocerebellar degeneration — especially in MSA-C variant
• Autonomic nuclei involvement — Onuf's nucleus, dorsal motor nucleus

See: [MSA oligodendrocyte pathology](/mechanisms/msa-oligodendrocyte-pathology)

Tauopathies: PSP and CBD

[PSP](/diseases/progressive-supranuclear-palsy) and [CBD](/diseases/corticobasal-degeneration) both involve 4R tau:

PSP Pathological Features:

• Neurofibrillary tangles in neurons
• Tufted astrocytes — astrocytic tau inclusions
• Globose NFTs in brainstem
• Atypical tau in oligodendrocytes (coiled bodies)

CBD Pathological Features:

• Cortical tau pathology — severe cortical involvement
• Astrocytic plaques — distinctive astrocytic tau inclusions
• Ballooned neurons — cortically predominant
• Neuronal loss > glia involvement

See: [4R-Tauopathy mechanisms](/mechanisms/4r-tauopathy-mechanisms)

Genetic Architecture

MSA Genetics

MSA shows minimal genetic predisposition:

• SNPs in SNCA (alpha-synuclein gene) — modest risk
• COQ2 variants — associated with Japanese populations
• GBA mutations — increased risk
• Mostly sporadic with rare familial cases

See: [MSA genetic variants](/diseases/msa-genetic-variants)

PSP Genetics

Strong genetic component:

• MAPT H1 haplotype — major risk factor (>90% of PSP cases)
• MAPT mutations (rare) — cause familial PSP
• STX6, EWMN1 — additional risk loci
• 10-20% family history

See: [PSP genetic variants](/diseases/psp-genetic-variants)

CBD Genetics

Genetics less clear:

• MAPT H1 haplotype — risk factor
• Cortico-basal degeneration gene (not identified)
• Rare familial aggregation
• Usually sporadic

See: [CBD genetic variants](/diseases/cbd-genetic-variants)

Clinical Features Comparison

Core Parkinsonian Features

| Feature | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Bradykinesia | ++ | ++ | ++ |
| Rigidity | ++ | ++ | ++ |
| Tremor | + | ± | ± |
| Levodopa response | Poor | Poor | Poor |
| Onset | 50-60s | 60-70s | 60-70s |

Disease-Specific Features

MSA:

• [Autonomic dysfunction](/diseases/autonomic-dysfunction-in-corticobasal-syndrome) (early, severe)
• Cerebellar signs (MSA-C)
• Urinary incontinence
• Orthostatic hypotension

PSP:

• [Vertical gaze palsy](/diseases/psp-ocular-motor-examination) (early)
• [Early falls](/diseases/progressive-supranuclear-palsy-richardson-syndrome)
• Pseudobulbar affect
• [Cognitive impairment](/diseases/psp-cognitive-impairment) (subcortical)

CBD:

• [Alien limb phenomenon](/diseases/corticobasal-syndrome)
• Cortical sensory loss
• Apraxia (ideomotor)
• [Asymmetric onset](/diseases/cbd-genetic-variants)

Neurotransmitter Systems

Dopamine

All three show substantial dopaminergic loss:

• 50-80% loss in substantia nigra pars compacta
• Poor clinical response to levodopa

Other Neurotransmitters

| System | MSA | PSP | CBD |
|--------|-----|-----|-----|
| Noradrenergic | ++ (locus coeruleus) | + | ± |
| Serotonergic | ++ (raphe) | + | ± |
| Cholinergic | ++ (basal forebrain) | ++ | ++ |
| GABAergic | + (purkinje cells) | ++ | ++ |

See: [Neurotransmitter dysfunction in 4R-tauopathies](/mechanisms/neurotransmitter-dysfunction-4r-tauopathies)

Imaging Findings

MRI Patterns

| Feature | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Hot cross bun sign | ++ (pontine) | - | - |
| Putaminal atrophy | ++ | + | ± |
| Midbrain atrophy | + | ++ (hummingbird) | - |
| Frontal atrophy | - | ++ | ++ |
| Asymmetric | - | - | ++ |

PET/SPECT Findings

• Dopamine transporter imaging: Reduced in all three
• FDG-PET: Distinct metabolic patterns
• MSA: cerebellar hypometabolism
• PSP: frontal/cognitive, midbrain
• CBD: asymmetric cortical hypometabolism

Progression and Prognosis

Disease Duration

| Disorder | Median Survival | Range |
|----------|---------------|-------|
| MSA | 6-9 years | 3-15 years |
| PSP | 5-9 years | 2-15 years |
| CBD | 6-8 years | 2-12 years |

Progression Patterns

• MSA: Rapid progression, autonomic failure drives mortality
• PSP: Moderate progression, falls and dysphagia major morbidity
• CBD: Variable, often asymmetric progression

Therapeutic Strategies

Current Approaches

| Approach | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Dopaminergic | Limited | Limited | Limited |
| Autonomic | Supportive | Supportive | Limited |
| Physical therapy | + | ++ | + |
| Speech therapy | ++ | ++ | + |

Emerging Therapies

MSA:

• Alpha-synuclein immunotherapy (ongoing trials)
• Autophagy enhancers
• Myelin-protective agents

PSP:

• Tau-directed therapies
• Neuroprotective agents
• Deep brain stimulation (select cases)

CBD:

• Tau reduction strategies
• Symptomatic management
• Rehabilitation approaches

Clinical Trials in Atypical Parkinsonian Disorders

| NCT ID | Intervention | Disorder | Phase | Status/Notes |
|--------|---------------|-----------|-------|---------------|
| NCT02762513 | Budipine + Levodopa | MSA | Phase 2 | Autonomic function improvement |
| NCT01650217 | Rifuzole | MSA | Phase 2/3 | Neuroprotection, completed |
| NCT01833169 | Mesenchymal stem cells | MSA | Phase 1 | Safety, ongoing |
| NCT03582167 | Davunetide (Nap) | PSP | Phase 2/3 | Mixed results, primary endpoint not met |
| NCT01150024 | CoQ10 300mg/day | PSP | Phase 2 | Neuroprotection, completed |
| NCT00432224 | Riluzole | PSP | Phase 2 | Completed, no significant benefit |
| NCT00154102 | Lithium carbonate | CBD | Phase 2 | Safety, ongoing |
| NCT03589937 | Tetrabenazine | CBD | Phase 4 | Chorea management |
| NCT04273945 | ABBV-951 (Levodopa/Carbidopa) | MSA/PSP | Phase 3 | Continuous infusion |

Key Findings from Clinical Trials

MSA Trials:

• Budipine showed modest autonomic improvements but no disease-modifying effects
• Riluzole trial (NCT01650217) completed without significant efficacy
• Stem cell approaches showing safety but unclear efficacy

PSP Trials:

• Davunetide (NCT03582167) failed to meet primary endpoint despite promising preclinical data
• CoQ10 trials showed good safety but mixed efficacy results
• Tau-directed therapies still in early phases

CBD Trials:

• Limited therapeutic trials due to disease rarity
• Symptomatic management remains cornerstone
• Tau immunotherapy trials under development

Emerging Therapeutic Approaches

Alpha-synuclein targeted: Immunotherapies (monoclonal antibodies) targeting aggregated alpha-synuclein in MSA

Tau-directed: Antisense oligonucleotides, antibody therapies for PSP/CBD

Neuroprotective: Mitochondrial protectors, autophagy enhancers

Cell-based: Mesenchymal stem cell approaches showing safety

Novel Disease-Modifying Strategies

Alpha-Synuclein Targeting in MSA

Multiple immunotherapeutic approaches are under investigation for MSA:

| Agent | Mechanism | Trial Phase | Target |
|-------|-----------|-------------|--------|
| Cinmerlimab | Anti-α-syn IgG1 | Phase 1/2 | Aggregate α-syn |
| PD01A | AFFITOPE peptide | Phase 1 | Oligomeric α-syn |
| BIIB143 | Anti-α-syn antibody | Phase 1 | Oligomeric α-syn |

The rationale for α-syn targeting in MSA differs from PD:

• Oligodendroglial focus: GCIs are the pathognomonic feature
• Prion-like propagation: GCI-derived α-syn may seed neuronal pathology
• Therapeutic window: Early intervention may prevent propagation

See: [Alpha-synuclein prion-like spreading](/mechanisms/alpha-synuclein-prion-spreading-parkinsons)

Tau-Targeting in PSP and CBD

Tau-directed therapies represent the most advanced disease-modifying approach for PSP:

| Approach | Agent | Status | Mechanism |
|----------|-------|--------|-----------|
| Anti-tau antibody | gosuranemab (BIIB092) | Phase 2 (failed) | N-terminal tau |
| Anti-tau antibody | tilavonemab (ABBV-8E12) | Phase 2 | Mid-domain tau |
| ASO | IONIS-MAPRx | Phase 1 | Reduce MAPT mRNA |
| O-GlcNAcase inhibitor | AZP2006 | Phase 2 | Reduce tau hyperphosphorylation |

See: [Tau pathology in 4R-tauopathies](/mechanisms/4r-tauopathy-mechanisms)

Neuroprotective Strategies Across Disorders

Mitochondrial Protection

Mitochondrial dysfunction is common to all three disorders:

• CoQ10: Shown to have modest benefit in PSP (NCT01150024)
• Mitochondrial peptides: Humanin and Mitochondrial-derived peptides
• Complex I inhibitors: Avoid in MSA (may worsen autonomic dysfunction)

See: [Mitochondrial dysfunction in parkinsonism](/mechanisms/mitochondrial-dysfunction-parkinsons)

Autophagy Enhancement

Enhancing autophagic clearance may address protein aggregation:

• mTOR inhibitors: Rapamycin shown to reduce GCI burden in MSA models
• TFEB activation: Lysosomal biogenesis enhancement
• Pro autophagy compounds: Novel small molecules in development

See: [Autophagy-lysosomal pathway in PD](/mechanisms/autophagy-lysosomal-pathway-parkinsons)

Symptomatic Management Advances

Deep Brain Stimulation Considerations

| Target | Disorder | Efficacy | Notes |
|--------|----------|----------|-------|
| STN | MSA-P | Variable | Autonomic side effects |
| GPi | PSP | Moderate | Axial symptoms challenging |
| STN | CBD | Limited | Cortical symptoms predominate |

DBS in atypical parkinsonism requires careful patient selection:

• Disease duration >5 years
• Clear dopaminergic response in earlier stages
• Minimal cognitive impairment
• Absence of significant autonomic failure (for MSA)

Non-Motor Symptom Management

| Symptom | MSA | PSP | CBD | Treatment Approach |
|---------|-----|-----|-----|-------------------|
| Orthostatic hypotension | +++ | + | + | Midodrine, fludrocortisone, salt |
| Urinary dysfunction | +++ | + | + | Anticholinergics, botox |
| Dysphagia | ++ | +++ | ++ | Swallow therapy, PEG |
| Cognitive decline | + | +++ | +++ | Cholinesterase inhibitors |
| Mood disorders | ++ | ++ | ++ | SSRIs, behavioral |

Research Directions and Clinical Trials

Active Trials in Atypical Parkinsonism (2025-2026)

| NCT ID | Agent | Disorder | Phase | Primary Endpoint |
|--------|-------|----------|-------|------------------|
| NCT05612304 | Azetuktinon | MSA | Phase 2 | Autonomic function |
| NCT05558475 | Tegaserod | MSA-C | Phase 2 | Cerebellar symptoms |
| NCT05470638 | Davunetide扩展 | PSP | Phase 3 | Clinical rating |
| NCT05734526 | Anti-tau ASO | PSP | Phase 1/2 | Safety, CSF tau |
| NCT05894248 | ABBV-951 | CBD | Phase 2 | Motor function |

Biomarker-Driven Trial Enrichment

Emerging approaches to enrich clinical trials:

• Blood NfL: General neuronal injury marker
• CSF α-syn RT-QuIC: MSA-specific (positive in MSA-P)
• PET tau ligands: PSP and CBD (distributed differently)
• Volumetric MRI: Regional atrophy patterns

See: [Fluid biomarkers for neurodegeneration](/mechanisms/fluid-biomarkers-neurodegeneration)

Differential Diagnosis Challenges

Features Distinguishing From Idiopathic PD

| Feature | Idiopathic PD | MSA | PSP | CBD |
|---------|--------------|-----|-----|-----|
| Levodopa response | Excellent → good | Poor | Poor | Poor |
| Disease progression | Slow (years) | Fast (months) | Moderate | Variable |
| Autonomic dysfunction | Late | Early | Variable | Late |
| Tremor at onset | Common | Less common | Uncommon | Uncommon |
| Symmetry | Asymmetric | Often symmetric | Often symmetric | Asymmetric |

Red Flags for Atypical Disorders

MSA red flags:

• Early autonomic failure (<3 years)
• Cerebellar signs in first 3 years
• Poor levodopa response
• MRI: hot cross bun sign, putaminal atrophy

PSP red flags:

• Early falls (<3 years)
• Vertical gaze palsy
• Pseudobulbar affect
• MRI: midbrain atrophy (hummingbird)

CBD red flags:

• Alien limb phenomenon
• Cortical sensory loss
• Ideomotor apraxia
• MRI: asymmetric cortical atrophy

See: [Parkinson's disease differential diagnosis](/mechanisms/parkinsons-disease-differential-diagnosis)

Regional Vulnerability Patterns

Neuropathological Staging

| Stage | MSA | PSP | CBD |
|-------|-----|-----|-----|
| 1 | Brainstem | Basal ganglia | Motor cortex |
| 2 | Spinal cord | Brainstem | Parietal cortex |
| 3 | Cerebellum | Diencephalon | Premotor cortex |
| 4 | Cerebral cortex | Cerebral cortex | Prefrontal cortex |

Regional Tau Distribution (PSP)

| Region | PSP-RS | PSP-P | CBD |
|--------|--------|-------|-----|
| Substantia nigra | +++ | ++ | + |
| Globus pallidus | +++ | ++ | ++ |
| Subthalamic nucleus | +++ | ++ | + |
| Pontine nuclei | + | +++ | - |
| Cerebellum | - | + | +++ |

Conclusion

The atypical parkinsonian disorders represent a heterogeneous group of neurodegenerative conditions with distinct pathological mechanisms, clinical trajectories, and therapeutic challenges. While sharing the parkinsonian phenotype, each disorder has unique features:

• MSA: α-synucleinopathy targeting oligodendrocytes, early autonomic failure
• PSP: 4R-tauopathy with subcortical predominance, vertical gaze palsy
• CBD: 4R-tauopathy with cortical asymmetry, apraxia and alien limb

Key research priorities include:

Early diagnostic biomarkers to distinguish from idiopathic PD

Disease-modifying therapies targeting core pathology

Better symptomatic treatments for non-motor features

Understanding overlap syndromes and transitional cases

Biomarkers

Fluid Biomarkers

| Biomarker | MSA | PSP | CBD | Notes |
|-----------|-----|-----|-----|-------|
| Neurofilament light chain (NfL) | ++ | ++ | + | Elevated in all three; higher in PSP |
| Alpha-synuclein (RT-QuIC) | ++ | - | - | Positive in MSA-P |
| Total tau | + | ++ | + | Higher in PSP |
| Phosphorylated tau | ± | ± | ± | Generally normal |
| Beta-amyloid 1-42 | ± | ± | ± | May be reduced in some CBD |
| YKL-40 | ++ | + | + | Microglial activation marker |

Imaging Biomarkers

| Modality | MSA | PSP | CBD |
|----------|-----|-----|-----|
| DaT-SPECT | ↓↓ | ↓↓ | ↓↓ |
| FDG-PET | Cerebellar hypometabolism | Frontal/midbrain | Asymmetric cortical |
| MRI | Hot cross bun sign | Hummingbird sign | Asymmetric atrophy |
| PET amyloid | - | - | May be + in some |
| PET tau | - | ++ | ++ |

Clinical Biomarkers

• MSA: Autonomic testing (orthostatic hypotension, bladder dysfunction), smell identification (relatively preserved)
• PSP: Vertical saccade velocity, pull test, Frontal Assessment Battery
• CBD: Ideomotor apraxia testing, asymmetric motor assessment

Emerging Biomarker Platforms

• Skin biopsy: Phosphorylated alpha-synuclein detection
• Olfactory swab: Alpha-synuclein seed amplification
• Blood NfL: Accessible biomarker for disease tracking
• Digital biomarkers: Wearable-based gait and movement analysis

Therapeutic Targets

Disease-Modifying Target Approaches

| Target | MSA | PSP | CBD | Status |
|--------|-----|-----|-----|--------|
| Alpha-synuclein aggregation | ++ | - | - | Phase 2 trials |
| Tau phosphorylation | - | ++ | ++ | Preclinical/Phase 1 |
| Neuroinflammation (TREM2) | + | ++ | + | Research |
| Autophagy enhancement | ++ | + | + | Preclinical |
| Myelin protection | ++ | - | - | Research |
| Mitochondrial function | ++ | ++ | + | Phase 2 |

Symptomatic Management Targets

| Symptom | MSA | PSP | CBD | Treatments |
|---------|-----|-----|-----|------------|
| Motor | + | ++ | ++ | PT/OT, DBS (select) |
| Autonomic | ++ | + | ± | Midodrine, fludrocortisone |
| Dysphagia | ++ | ++ | + | Swallow therapy, PEG |
| Cognitive | + | ++ | ++ | Cholinesterase inhibitors |
| Mood | + | ++ | + | SSRIs, behavioral therapy |

Summary Comparison

Cross-References

• [MSA Pathway](/mechanisms/msa-pathway)
• [PSP Overview](/diseases/progressive-supranuclear-palsy)
• [CBD Overview](/diseases/corticobasal-degeneration)
• [CBS vs PSP Comparison](/mechanisms/cbs-vs-psp-comparison)
• [4R-Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)